financetom
Business
financetom
/
Business
/
UPS Q2 Earnings: Revenue And EPS Miss, Annual Outlook Cut, Restarts Stock Buyback
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UPS Q2 Earnings: Revenue And EPS Miss, Annual Outlook Cut, Restarts Stock Buyback
Jul 23, 2024 5:19 AM

United Parcel Service Inc ( UPS ) shares are trading lower after it reported second-quarter 2024 results.

Revenue declined 1.1% year-over-year to $21.82 billion, missing the consensus of $22.183 billion. Adjusted EPS was $1.79, down 29.5% YoY, missing the consensus of $1.99.

Consolidated operating profit fell 30.1% YoY to $1.9 billion; consolidated operating margin stood at 8.9%, while adjusted consolidated operating margin was 9.5%.

U.S. Domestic Segment revenue fell 1.9% YoY to $14.12 billion, reflecting a 2.6% decrease in revenue per piece due to changes in product mix. The adjusted operating margin stood at 7.1%.

International Segment revenue decreased by 1% YoY to $4.37 billion, owing to a 2.9% decrease in average daily volume. The adjusted operating margin was 18.9%.

Supply Chain Solutions Segment revenue increased by 2.6% to $3.33 billion, reflecting growth in logistics, including healthcare. The adjusted operating margin was 7.3%.

UPS’ operating cash flow for six months ended June 30, 2024, totaled $5.309 billion, and free cash flow was $3.365 billion.

2024 Outlook, updated: UPS now expects revenue of ~$93 billion (prior $92 billion-$94.5 billion) versus the $92.794 billion consensus and sees an adjusted operating margin of 9.4% (prior 10%-10.6%).

UPS expects 2024 capital expenditures of about $4 billion.

The company restarted its repurchase program, targeting around $1 billion annually.

Yesterday, UPS announced the acquisition of Estafeta, a Mexican express delivery company, to leverage Mexico’s manufacturing boom, global supply chain shifts, and North American trade growth. This move aligns with UPS’s strategy to enhance its global logistics capabilities, providing seamless service and greater efficiency.

Price Action: UPS shares are trading lower by 7.77% at $133.90 premarket at the last check on Tuesday.

Image via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion
Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion
Apr 22, 2024
08:49 AM EDT, 04/22/2024 (MT Newswires) -- Lantern Pharma ( LTRN ) said Monday it has received regulatory approval to expand its Harmonic trial in Japan and Taiwan, a phase 2 clinical study of LP-300 in non-small cell lung cancer in never-smokers, the company added. LP-300, a therapeutic to treat relapsed and inoperable primary adenocarcinoma of the lung given in...
Satellogic Commits to Backing Amazon Rainforest Monitoring Project
Satellogic Commits to Backing Amazon Rainforest Monitoring Project
Apr 22, 2024
08:49 AM EDT, 04/22/2024 (MT Newswires) -- Satellogic ( SATL ) said Monday it signed a letter of intent with O.N.E. Amazon to advance conservation goals. Financial terms of the preliminary deal were not disclosed. Satellogic ( SATL ) will use its technology to power O.N.E. Amazon's project to create what it describes as an Internet of Forests, a network...
Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug
Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug
Apr 22, 2024
08:47 AM EDT, 04/22/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Monday that it has signed an in-license agreement with Cornell University to expedite the development of investigational gene therapy candidate LX2006 to treat Friedreich ataxia cardiomyopathy. Under the deal, Lexeo said it has acquired certain rights, including rights to current and future data generated in an ongoing...
IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy
IDEAYA Biosciences Selects Move-Forward Expansion Dose for Mid-Stage Trial of IDE397 Monotherapy
Apr 22, 2024
08:45 AM EDT, 04/22/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Monday that it has selected a move-forward expansion dose for a mid-stage trial evaluating its IDE397 monotherapy in MTAP-deletion squamous non-small cell lung cancer, or NSCLC. Squamous NSCLC has been identified as the most sensitive tumor type of IDE397 monotherapy, the company said. There are more than...
Copyright 2023-2026 - www.financetom.com All Rights Reserved